DURAVYU治疗湿性AMD首个III期临床试验完成受试者入组

贝达药业投资者...
28 May

北京时间5月27日,贝达药业战略合作伙伴EyePoint Pharmaceuticals, Inc.(纳斯达克股票代码:EYPT,以下简称“EyePoint”)宣布, 其治疗湿性年龄相关性黄斑变性(湿性AMD)药物DURAVYU™的首个关键性III期LUGANO临床试验完成受试者入组。LUGANO试验在短短七个月内完成入组,是迄今为止湿性AMD关键性III期临床试验最快入组速度之一。LUGANO和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10